Skip to Main Content

Amid global anxiety over the novel coronavirus, a newly issued warning letter by the Food and Drug Administration serves as a reminder that quality manufacturing needs to remain a priority.

Consider the March 17 missive sent to Windlas Healthcare, which formulates finished medicines for some of the world’s largest drug makers. The company committed several serious infractions that alarmed the agency following an August 2019 inspection of a manufacturing facility in northern India.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.